BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.
NCT ID: NCT00493623
Last Updated: 2016-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
68 participants
INTERVENTIONAL
2007-06-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
NCT00493532
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
NCT00129623
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
NCT00545207
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT02604836
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
NCT01128257
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ibandronate [Bonviva/Boniva]
3mg i.v. single dose
2
Placebo
Placebo i.v. single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo i.v. single dose
ibandronate [Bonviva/Boniva]
3mg i.v. single dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* osteoporosis;
* vertebral osteoporotic fracture in past 4 weeks;
* fracture-related pain requiring analgesic treatment.
Exclusion Criteria
* current treatment with another bisphosphonate;
* current treatment with class III analgesics.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aix-en-Provence, , France
Amiens, , France
Angers, , France
Bonneville, , France
Bordeaux, , France
Caen, , France
Cannes, , France
Clermont-Ferrand, , France
Échirolles, , France
Lille, , France
Lomme, , France
Marseille, , France
Marseille, , France
Montpellier, , France
Mulhouse, , France
Nantes, , France
Nice, , France
Orléans, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Rennes, , France
Rouen, , France
Saint-Priest-en-Jarez, , France
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML19360
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.